

Datasheet: MCA477SBB700

BATCH NUMBER 100004825

| | |
|----------------------|---|
| Description: | MOUSE ANTI HUMAN HLA DP DQ DR:StarBright Blue 700 |
| Specificity: | HLA DP DQ DR |
| Format: | StarBright Blue 700 |
| Product Type: | Monoclonal Antibody |
| Clone: | WR18 |
| Isotype: | IgG2a |
| Quantity: | 100 TESTS/0.5ml |

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

| | Yes | No | Not Determined | Suggested Dilution |
|----------------|-----|----|----------------|--------------------|
| Flow Cytometry | ▪ | | | Neat |

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

| | | | |
|------------------------|---|----------------------------|--------------------------|
| Target Species | Human | | |
| Product Form | Purified IgG conjugated to StarBright Blue 700 - liquid | | |
| Max Ex/Em | Fluorophore | Excitation Max (nm) | Emission Max (nm) |
| | StarBright Blue 700 | 470 | 700 |
| Preparation | Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant | | |
| Buffer Solution | Phosphate buffered saline | | |
| Preservative | 0.09% Sodium Azide (NaN ₃) | | |
| Stabilisers | 1% Bovine Serum Albumin | | |
| | 0.1% Pluronic F68 | | |
| | 0.1% PEG 3350 | | |
| | 0.05% Tween 20 | | |

| | |
|------------------------|--|
| Immunogen | Human HLA Class II (DP, DQ, DR). |
| Fusion Partners | Spleen cells from immunised BALB/c mice were fused with cells from NS0 mouse myeloma cell line. |
| Specificity | <p>Mouse anti Human HLA DP DQ DR antibody, clone WR18 reacts with a monomorphic determinant common to DP, DQ and DR beta chains, which are expressed by antigen presenting cells, B cells, monocytes and activated T lymphocytes.</p> <p>The major histocompatibility complex (MHC) is a cluster of genes that are important in the immune response to infections. In humans, this complex is referred to as the human leukocyte antigen (HLA) region. There are 3 major MHC class II proteins encoded by the HLA which are HLA DP, HLA DQ and HLA DR.</p> |
| Flow Cytometry | Use 5ul of the suggested working dilution to label 10 ⁶ cells in 100ul. Best practices suggest a 5 minutes centrifugation at 6,000g prior to sample application. |
| References | <ol style="list-style-type: none"> 1. Moore, K. <i>et al.</i> (1987) Use of the monoclonal antibody WR17, identifying the CD37 gp40-45 Kd antigen complex, in the diagnosis of B-lymphoid malignancy. J Pathol 152:13-21. 2. Kissner, T.L. <i>et al.</i> (2011) Activation of MyD88 Signaling upon Staphylococcal Enterotoxin Binding to MHC Class II Molecules. PLoS One. 6: e15985. 3. Chia, J.S. <i>et al.</i> (2001) Human T-cell responses to the glucosyltransferases of <i>Streptococcus mutans</i>. Clin Diagn Lab Immunol. 8: 441-5. 4. Chang, Y.C. <i>et al.</i> (2008) Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3. Blood. 111: 5054-63. 5. Litzinger, M.T. <i>et al.</i> (2009) Chronic lymphocytic leukemia (CLL) cells genetically modified to express B7-1, ICAM-1, and LFA-3 confer APC capacity to T cells from CLL patients. Cancer Immunol Immunother. 58: 955-65. 6. Sadallah, S. <i>et al.</i> (2011) Microparticles (ectosomes) shed by stored human platelets downregulate macrophages and modify the development of dendritic cells. J Immunol. 186: 6543-52. 7. Sabbah, S. <i>et al.</i> (2012) T-cell immunity to Kaposi sarcoma-associated herpesvirus: recognition of primary effusion lymphoma by LANA-specific CD4+ T cells. Blood. 119 (9): 2083-92. 8. John, J. <i>et al.</i> (2010) Differential effects of Paclitaxel on dendritic cell function. BMC Immunol. 11:14. 9. Palmer, K.J. <i>et al.</i> (2000) Interferon-alpha (IFN-alpha) stimulates anti-melanoma cytotoxic T lymphocyte (CTL) generation in mixed lymphocyte tumour cultures (MLTC). Clin Exp Immunol. 119: 412-8. 10. Silk, K.M. <i>et al.</i> (2012) Rapamycin conditioning of dendritic cells differentiated from human ES cells promotes a tolerogenic phenotype. J Biomed Biotechnol. 2012: 172420. 11. Elias, F. <i>et al.</i> (2003) Strong cytosine-guanosine-independent immunostimulation in humans and other primates by synthetic oligodeoxynucleotides with PyNTTTTGT motifs. J Immunol. 171: 3697-704. 12. Silk, K.M. <i>et al.</i> (2012) Cross-presentation of tumour antigens by human induced pluripotent stem cell-derived CD141(+)/XCR1+ dendritic cells. Gene Ther. 19 (10): 1035-40. |

13. Adamski, J. (2004) 17{beta}-Estradiol Inhibits Class II MHC Expression: Influence on Histone Modifications and CBP Recruitment to the Class II MHC Promoter [Molecular Endocrinology 18:1963](#)
14. Keating, S. *et al.* (2002) The lytic cycle of Epstein-Barr virus is associated with decreased expression of cell surface major histocompatibility complex class I and class II molecules. [J Virol. 76: 8179-88.](#)
15. Trefzer, U. *et al.* (2000) Hybrid cell vaccination for cancer immune therapy: first clinical trial with metastatic melanoma. [Int J Cancer. 85 \(5\): 618-26.](#)
16. Hayman, M.W. *et al.* (2006) Soluble human leukocyte antigen: a diagnostic indicator of rheumatoid arthritis? [J Immunol Methods. 315 \(1-2\): 19-26.](#)
17. Manna, D. *et al.* (2012) WR18 MONOCLONAL ANTIBODY: A SINGLE ANTIBODY TO DETECT HLA DR, DP AND DQ ANTIGENS. [Abstracts/Human immunology 73:49-167 abstract 36P](#)
18. Neumann, F. *et al.* (2004) Identification of an antigenic peptide derived from the cancer-testis antigen NY-ESO-1 binding to a broad range of HLA-DR subtypes. [Cancer Immunol Immunother. 53 \(7\): 589-99.](#)
19. Neumann F *et al.* (2004) Identification of an HLA-DR-restricted peptide epitope with a promiscuous binding pattern derived from the cancer testis antigen HOM-MEL-40/SSX2. [Int J Cancer. 112 \(4\): 661-8.](#)
20. Iking-Konert C *et al.* (2005) Transdifferentiation of polymorphonuclear neutrophils to dendritic-like cells at the site of inflammation in rheumatoid arthritis: evidence for activation by T cells. [Ann Rheum Dis. 64 \(10\): 1436-42.](#)
21. Hönger, G. *et al.* (2015) Inter-individual differences in HLA expression can impact the CDC crossmatch. [Tissue Antigens. 85 \(4\): 260-6.](#)
22. del Pilar Martin, M. *et al.* (2008) Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. [Arch Neurol. 65 \(12\): 1596-603.](#)
23. Noble, P. *et al.* (2013) High levels of cleaved caspase-3 in colorectal tumour stroma predict good survival. [Br J Cancer. 108 \(10\): 2097-105.](#)
24. Llewelyn, M. *et al.* (2004) HLA class II polymorphisms determine responses to bacterial superantigens. [J Immunol. 172 \(3\): 1719-26.](#)
25. Koschwanez, H. *et al.* (2015) Stress-related changes to immune cells in the skin prior to wounding may impair subsequent healing. [Brain Behav Immun. 50: 47-51.](#)
26. Ziegler, C.G.K. *et al.* (2019) Constitutive Activation of the B Cell Receptor Underlies Dysfunctional Signaling in Chronic Lymphocytic Leukemia. [Cell Rep. 28 \(4\): 923-937.e3.](#)

Storage

Store at +4°C. DO NOT FREEZE.
This product should be stored undiluted.

Guarantee

12 months from date of despatch

Acknowledgements

This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts

Health And Safety Information

Material Safety Datasheet documentation #20471 available at:
<https://www.bio-rad-antibodies.com/SDS/MCA477SBB700>
20471

Related Products

Recommended Useful Reagents

[HUMAN SEROBLOCK \(BUF070A\)](#)

[HUMAN SEROBLOCK \(BUF070B\)](#)

North & South Tel: +1 800 265 7376

America Fax: +1 919 878 3751

Email: antibody_sales_us@bio-rad.com

Worldwide

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: antibody_sales_uk@bio-rad.com

Europe

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: antibody_sales_de@bio-rad.com

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets

'M373709:200929'

Printed on 08 Mar 2024